Regimen failure through 48 weeks was 22.8% with long-acting cabotegravir plus rilpivirine versus 41.2% with continued daily oral ART in adherence-challenged adults with HIV who achieved initial suppression before randomization. Virologic failure occurred in 5 of 152 on injectables versus 32 of 154 on oral therapy; permanent treatment discontinuation was 24 and 23, respectively. Adverse events were comparable between arms; injection-site reactions occurred in 60% of the long-acting group with two discontinuations. Resistance-associated mutations emerged in four participants total, two per arm.
The New England Journal of Medicine publication of LATITUDE (A5359), an NIH-sponsored Phase 3 study, formalizes the first randomized evidence that long-acting treatment can outperform daily pills in people with documented adherence challenges. Among 453 enrolled who struggled with oral ART or had disengaged from care, 306 who achieved viral suppression following structured adherence support (including economic incentives) were randomized to monthly injections or continuation of oral standard of care. A February 2024 DSMB decision halted randomization early for efficacy and invited eligible participants to transition to the injectable regimen.
Strategically, this result pressures a long-standing operational and regulatory boundary: long-acting formulations have largely been deployed for stable, already adherent patients. LATITUDE shows that the spacing and accountability of clinic-administered dosing can reduce failure rates, driven primarily by lower virologic failure, in a population that the label and earlier registrational programs largely sidestepped. For manufacturers, the signal validates a public-health expansion thesis for long-acting treatment that goes beyond convenience positioning. For guideline bodies and payers, it reframes injectables as an adherence intervention rather than a lifestyle option.
The implications for delivery are immediate. HIV clinics, FQHCs, and public health programs could see increased demand for monthly or every-two-month injection services, with associated scheduling, inventory management, and reimbursement under the medical benefit. Missed-visit management, oral bridging protocols, and recall systems become central risk controls to prevent resistance accumulation in the long pharmacologic tail. Sites will need staffing and capacity for walk-in or same-day injections, cold-chain reliability, and integration with outreach teams serving mobile populations. CROs and sponsors should note that LATITUDE embedded a pre-randomization stabilization phase with adherence supports; future pivotal and pragmatic studies in infectious diseases may increasingly incorporate behavioral and structural interventions as core design elements rather than ancillary services.
For regulators, the study fits within the current U.S. approval context by randomizing only after suppression, but the population profile—and the DSMB’s efficacy stop—may catalyze discussions on labeling language, postmarketing commitments, and real-world evidence to support use in individuals with recent viremia or care disengagement. Payers and Ryan White programs will face coverage decisions around buy-and-bill workflows, missed-injection policies, and support for transportation and outreach. The demography of the trial—majority Black participants, substantial representation of women and people with a history of injection drug use—aligns with equity priorities and may accelerate guideline uptake.
Next, watch for implementation data on retention and missed-dose rescue in community settings, potential expansion to every-two-month dosing in this population, and health-economic analyses weighing clinic-administered costs against reductions in virologic failure and care re-engagement burden. Any move toward broader labeling or guideline language will hinge on durability beyond 48 weeks and the robustness of operational models that maintain appointment adherence. The swing to clinic-anchored long-acting regimens as an adherence tool is clear; the competitive edge will go to programs that solve logistics at scale without amplifying access friction.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
